employer coverage glp-1 news october 2025 Perspectives from employers on the costs and issues associated with covering agonists for weight loss Weight loss drugs' high costs

The company announced yesterday that it has officially begun enrolling participants in a Phase 2 trial of pemvidutide, its GLP-1 and glucagon dual receptor agonist, to evaluate the drug in people with Alcohol Use Disorder, or AUD

injections of GLP-1:GIP, GLP-1:GIP:Lani, Lani or vehicle for 12 days

The individual peptide research that informs blend dosing used weight-based calculations, and applying the same logic to the blend improves precision

Bukan hanya menawarkan keseruan, tetapi juga potensi keuntungan yang besar

The two most well-known injectable brands, Ozempic and Wegovy, have slightly different rules for how long they can stay out of the refrigerator